Position in GRFS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$599,017
+$219,527 QoQ
Shares Held
84,607
+78.8% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#51
of 164 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Vinva Investment Management Ltd holds $708,443,081 across 10 Drug Manufacturers - General names. GRFS ranks #10 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
180,920 | $217,000,893 | |
| 2 | ABBV |
AbbVie Inc.
|
511,672 | $128,757,142 | |
| 3 | JNJ |
Johnson & Johnson
|
450,629 | $114,446,247 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
1,870,866 | $107,799,298 | |
| 5 | AMGN |
Amgen Inc
|
131,323 | $47,554,684 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
318,895 | $40,289,194 | |
| 7 | MRK |
Merck & Co., Inc.
|
298,766 | $38,391,431 | |
| 8 | PFE |
Pfizer Inc
|
510,661 | $12,296,716 |
All Filings in GRFS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $599,017 | 84,607 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $379,490 | 47,318 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $263,885 | 28,223 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $255,623 | 25,665 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $256,211 | 28,342 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||